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Abstract
Background: Mechanisms driving cancer-induced bone pain are poorly understood. A central factor implicated to
be a key player in the process of tumorigenesis, osteoclastogenesis and nociception is p38 MAPK. We determined
the role of p38 MAPK in a mouse model of breast cancer induced bone pain in which mixed osteolytic and
osteoblastic remodeling occurs.
Results: In cancer-treated mice, acute as well as chronic inhibition of p38 MAPK with SB203580 blocked flinching
and guarding behaviors in a dose-dependent manner whereas no effect on thresholds to tactile stimuli was
observed. Radiographic analyses of bones demonstrated that chronic inhibition of p38 MAPK reduced bone loss
and incidence of spontaneous fracture in cancer-treated mice. Histological analysis of bones collected from mice
treated with the p38 MAPK inhibitor showed complete absence of osteoblastic growth in the intramedullary space
as well as significantly reduced tumor burden.
Conclusions: Blockade of non-evoked pain behaviors but not hypersensitivity suggests differences in the
underlying mechanisms of specific components of the pain syndrome and a possibility to individualize aspects of
pain management. While it is not known whether the role of p38 MAPK signaling can be expanded to other
cancers, the data suggest a need for understanding molecular mechanisms and cellular events that initiate and
maintain cancer-induced bone pain for effective management for both ongoing pain as well as breakthrough pain.
Background
Chronic pain is experienced by 30-50% of all cancer
patients irrespective of the stage and 70-90% of those with
advanced metastatic disease [1,2]. Cancer pain is multifa-
ceted with varying degrees of intensity, at multiple anato-
mical locations, and characterized by multiple pain
descriptors including inflammatory, neuropathic and
mechanical that likely have different underlying mechan-
isms [3,4]. The most commonly diagnosed cancers such as
those of lung, prostate, and breast often metastasize to the
bone [5,6] and are associated with bone remodeling and
eventual bone fractures that contribute to incapacitating
pain and limited or total loss of mobility and daily activity.
Even though pain is the most frequent and disruptive
symptom of the disease, mechanisms that initiate and
maintain cancer-induced pain are not clearly understood.
This ultimately results in poor pain management as the
analgesic treatments (e.g. opiates, bisphosphonates) cur-
rently used to treat cancer-induced bone pain are given
across prolonged periods of time and are associated with
debilitating side effects [7,8] Overall, pain management
still remains inadequate in approximately 40% of cancer
patients [9,10]. As advances in cancer therapeutics have
drastically increased life expectancy of patients, including
those with bone metastases, these patients continue to
experience pain that can be severe and unpredictable,
greatly limiting daily activity resulting in poor quality of
life [11,12]. This highlights the need for effective treatment
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opment of debilitating side effects associated with cur-
rently available treatments.
One potential mediator of tumor-induced bone pain is
p38 MAPK, a serine/threonine mitogen activated protein
kinase activated by its phosphorylation in various signaling
cascades [13-15]. The p38 MAPK signaling pathway has
been implicated in mediating inflammatory and neuro-
pathic pain, both of which are thought to contribute to can-
cer-induced bone pain [16-18]. Moreover, p38 MAPK has
also been demonstrated to be important in maturation and
synthesis of osteoclasts, cells responsible for osteolysis
[19,20]. The p38 MAPK cascade is known to be activated
by tumor-induced cellular stress such as inflammatory
cytokines [21]. In addition, it is also established as a key
player in the induction of cellular effects of cytokines such
as Tumor Necrosis Factor a (TNFa)a n dI n t e r l e u k i n - 1 b
[22-25]. The growing tumor burden, acidic tumor microen-
vironment, an array of inflammatory mediators produced
by the tumor and tumor associated cells in the bone micro-
environment and tumor-induced bone degradation all
contribute to bone pain [26]. As p38 MAPK plays a key
role in each of these variables, we hypothesized that block-
ade of p38-MAPK signaling might attenuate cancer-
induced bone pain and bone loss. The present study deter-
mined the role of p38 MAPK in tumor growth, tumor-
induced bone loss, and components of tumor-induced
bone pain in a mouse model of cancer-induced bone pain
in which mammary adenocarcinoma cells were injected
and sealed into the intramedullary space of the femur of
female mice to allow controlled progression of disease
within the bone.
Results
Implantation of breast cancer cells 66.1 into the
intramedullary space of the femur induces pain-like
behaviors in mice
Injection of the mouse breast cancer cells into the femur
produced a time-dependent expression of both non-
evoked pain-like behaviors (flinching and guarding) as
well as changes in sensory thresholds to evoked stimuli
(Figure 1). Cancer-treated mice demonstrated flinching
Figure 1 Time course for emergence of pain behaviors showing spontaneous flinching (A), spontaneous guarding (B), tactile allodynia
(C) and limb use score (D). n = 8 mice/group.
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behavior continuing to increase through the day 14
time-point. (Figure 1A). Cancer-treated mice showed
significant guarding behavior within 7 days post-surgery,
which increased by day 13 (Figure 1B). Cancer-treated
mice showed robust tactile hypersensitivity by the day 7
time-point, with paw withdrawal thresholds remaining
low throughout the testing period (Figure 1C). Control
mice showed slightly lowered withdrawal thresholds at
day 7 post-surgery, with withdrawal thresholds returning
to baseline by the day 9 time-point. Both cancer-treated
and control mice showed impaired limb use on day 7
following the surgery (Figure 1D). Cancer-treated mice
showed greater impairment of limb use than control
mice, demonstrating both limping and guarding behaviors
whereas control mice only showed transient limping beha-
viors, likely due to surgery induced pain. Impaired limb
use was not observed at later time points in control mice
whereas cancer-treated mice continued to guard and/or
limp through day 14 post-surgery (Figure 1D).
Implantation of breast cancer cells 66.1 into the
intramedullary space of femur induces bone remodeling
and tumor growth
Femur radiographs showed a time-dependent change in
bone remodeling on days 7, 10, and 13 after the cancer
cells were injected (Figure 2A). In comparison with the
normal bone (Figure 2A, panel a), cancer-induced bone
remodeling was first evident on day 7 post-surgery (Fig-
u r e2 A ,p a n e lb )w i t hb o n el o s sa tt h ep r o x i m a le n do f
the bone (knee) at the epiphyseal plate region. Bone loss
increased and was extended to the shaft by day 10 post-
surgery (Figure 2A, panel c). On day 13 post-surgery, in
addition to the bone loss, abnormal bone growth was
observed within the shaft (Figure 2A, panel d). Histolo-
gical analyses of the bones show a time-dependent
growth of the tumor within the bone. Bones injected
with cell-free media showed normal marrow and contin-
uous cortical bone (Figure 2B, panels a,b). Bones col-
lected on day 3 post-surgery showed the presence of
tumor mass within the shaft at the site of injection (Fig-
ure 2B, panels c,d). By day 7, tumor burden increased
and filled the bone shaft replacing the marrow. In addi-
tion, cortical invasion by the tumor was also observed
(Figure 2B, panels e,f). On day 13, abnormal osteoblastic
b o n eg r o w t hw a ss e e ni nt h es h a f ta sw e l la sg r o w i n g
outside of the cortical bone (Figure 2B, panels g,h).
Acute administration of SB203580 attenuates breast
cancer induced non-evoked pain behaviors
Pre-drug testing demonstrated that all cancer treated
mice showed significant flinching and guarding beha-
viors 13 days post-surgery whereas control mice did not
show any flinching or guarding behavior (Figure 3A-D).
SB203580, a p38 MAPK inhibitor, was administered at
15 or 30 mg/kg, i.p. and flinching episodes (Figure 3A,
B) as well as time spent guarding (Figure 3C,D) were
evaluated across a 2 min period. SB203580 inhibited
flinching and guarding with peak drug effects were
observed at 60 min post administration (Figure 3A).
Flinching and guarding behaviors returned to pre-drug
levels by 180 min post administration. Acute systemic
administration of p38 MAPK inhibitor decreased flinch-
ing in a dose-dependent manner (Figure 3B). Time
spent guarding the cancer bearing limb was significantly
reduced in mice that received the highest dose (30 mg/
kg) of the drug (Figure 3D). Statistical comparison with
the pre-drug pain behaviors as well as the vehicle group
indicated that flinching was significantly reduced in
drug-treated mice at both doses but time spent guarding
was only reduced in the mice that received the highest
dose (30 mg/kg). Administration of saline vehicle did
not alter flinching or guarding in the cancer treated
mice.
Acute administration of SB203580 does not block breast
cancer induced tactile hypersensitivity
Pre-drug testing demonstrated that cancer treated mice
had decreased response thresholds to von Frey filaments
(Figure 3E,F). Acute administration of either dose (15 or
30 mg/kg, i.p.) of the SB203580 failed to diminish tactile
hypersensitivity of cancer bearing limb (Figure 3E,F).
Paw withdrawal thresholds of mice that received the
vehicle did not alter from the pre-drug threshold. Paw
withdrawal thresholds of the control mice remained
unchanged after the drug administration.
Chronic administration of SB203580 attenuates breast
cancer induced flinching and guarding
Before the drug treatment was started (D7), all mice
showed flinching and guarding pain behaviors as com-
pared to the controls (Figure 4A,C). Administration of
SB203580 (15 and 30 mg/kg, i.p. 2× daily across 7 days
starting day 7 post surgery) diminished cancer-induced
flinching episodes by D11 post-surgery as compared to
those that received vehicle (Figure 4A). By D13, flinching
was significantly attenuated in cancer bearing mice treated
with the drug (15 mg/kg and 30 mg/kg) compared to
those that received vehicle (Figure 4A,B). Cancer bearing
mice that received the drug showed reduced time spent
guarding the cancer bearing limb by D9 post-surgery and
remained diminished throughout the time course in mice
that received the drug as compared to those that received
the vehicle (Figure 4C,D). Control mice showed minimal
flinching and no guarding irrespective of drug treatment
on all the test days. Control or cancer treated mice did not
show any adverse drug-related effects on prolonged
administration of SB203580.
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cancer induced tactile hypersensitivity
Prior to drug treatment (Day 7), cancer-treated mice
demonstrated tactile hypersensitivity, as indicated by
lowered paw withdrawal thresholds to von Frey fila-
ments. Prolonged treatment with SB203580 (15 and 30
mg/kg) did not alter cancer-induced tactile hypersensi-
tivity across the entire testing period (p > 0.05, Figure
4E,F). Paw withdrawal latencies remained consistent in
control mice throughout the testing period irrespective
of drug treatment.
Chronic administration of SB203580 attenuates breast
cancer induced impaired limb use
Cancer bearing mice showed impaired limb use by day 7
post surgery as compared to the control mice which
Figure 2 Breast cancer cells when injected in the intramedullary space of the femur result into disease progression and tumor-
induced bone remodeling (A). Radiographic images show normal bone with no bone destruction (a), D7 post tumor implantation with little
bone loss (osteolytic remodeling; indicated by yellow arrows) observed in the shaft (b), D10 post tumor implantation with increased bone loss in
the shaft and knee area (c), D13 post tumor implantation with further increased bone loss in the shaft and the knee region, cortical fractures
(indicated by blue arrows) and abnormal bone growth in the shaft (osteoblastic remodeling, indicated by white arrows) (d), Histological analyses
of bones (B) show control bone with intact cortical bone and marrow components (a, b), presence of tumor in the intramedullary space D3 post
implantation (c, d), tumor invading into cortical bone and growing towards the epiphyseal plate of the knee by D7 post implantation (e,f),
tumor infiltrating the entire intramedullary space of the bone with woven bone formation along the cortex by D13(g,h); B, cortical bone; M,
bone marrow; T, tumor; EP, epiphyseal plate; WB, woven bone.
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Page 4 of 15Figure 3 Effects of acute administration of SB203580 (15 and 30 mg/kg, i.p.) at day 13 post-surgery on cancer-induced spontaneous
flinching (A, B), spontaneous guarding (C,D) and tactile allodynia (E,F). Time-course analyses indicate a time-dependent decrease in
spontaneous flinching (A) and guarding (C) but not tactile allodynia (E).
#indicates significant difference from pre-drug levels, *indicates significant
difference from the vehicle treated group (p < 0.05). Analysis of the peak effect (60 min post-administration, indicates decreased tumor-induced
flinching at both doses (B), decreased time spent guarding at the highest dose (D) and no change in tactile hypersensitivity (F). *indicates
significant difference from the vehicle treated group (p < 0.05). All graphs show means ± SEM, n = 10.
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Page 5 of 15Figure 4 Effects of chronic administration of SB203580 (15 and 30 mg/kg, i.p., 2× daily) on cancer-induced spontaneous flinching (A,B)
spontaneous guarding (C,D), tactile allodynia (E,F) and limb use (G,H). Time-course analysis indicate a time-dependent decrease in tumor-
induced spontaneous flinching (A) guarding (B) and limb use (E), but no change in tactile hypersensitivity (G). *indicates significant difference from
vehicle treated group. Analysis on day 13 demonstrates decreased flinching (B), guarding (D) and limb use (F) in cancer mice treated with 15 as
well as 30 mg/kg SB2035580. Chronic treatment with SB203580 failed to alter tactile hypersensitivity at either dose. *indicates significant difference
from cancer vehicle group (p < 0.05). All graphs show means ± SEM. n = 6-8.
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Page 6 of 15showed slight limping behaviors while walking (Figure
4G). By day 13 post surgery, significant improvement in
the limb use rating was observed by day 13 post surgery
in mice that received 15 as well as 30 mg/kg of
SB203580 as compared to vehicle treated mice (Figure
4d). Control mice regained normal limb use by day 9
and maintained throughout the testing period irrespec-
tive of drug treatment.
Chronic administration of SB203580 prevents and/or
delays breast cancer induced bone remodeling
Mice that received the vehicle demonstrated significant
bone loss at the epiphyseal region extending to the shaft
of the bone. An abnormal osteoblastic bone growth was
also observed at the epiphyseal plate and shaft (Figure 5A).
As many as 50% of mice in this group showed unicortical
or bicortical fractures (Figure 5B). In mice that received
15 mg/kg or 30 mg/kg of the drug, bone loss at both the
regions was greatly reduced, with no evidence of abnormal
bone growth (Figure 5A). In addition, prolonged
SB203580 treatment reduced incidence of cortical frac-
tures in a dose dependent manner, with only 30% (15 mg/
kg) and 15% (30 mg/kg) of the cancer treated mice show-
ing cortical fractures (Figure 5C). This indicates that pro-
longed inhibition of p38 MAPK diminished bone
remodeling. Control mice did not show any abnormal
bone remodeling upon drug treatment.
Chronic administration of SB203580 reduces tumor
growth within the intramedullary space of the bone and
in vitro
Bones collected from control mice showed apparently nor-
mal cortical bone and marrow components. Cancer-trea-
ted mice treated with vehicle showed complete infiltration
of the marrow by the growing tumor (Figure 6A, panels a,
b). Consistency of cortical bone was lost with multiple
fractures and abnormal osteoblastic growth throughout
the shaft induced by the growing tumor (Figure 6A, panels
a,b). In cancer- treated mice that received 15 mg/kg of the
drug, tumor growth was confined to the shaft in the mid-
dle of the intramedullary space where the breast cancer
cells were initially implanted. No tumor was evident
around the epiphyseal plate indicating the failure of
the cancer cells to migrate with SB203580 treatment
(Figure 6A panels c,d). In mice that received 30 mg/kg of
the drug, only a few tumor pockets were observed within
the intramedullary space. Additionally normal marrow
components were still present within the bone (Figure 6A
panels e,f). Quantification of the tumor-occupied area in
the intramedullary space of the bone indicate a two and
five fold reduction of tumor growth in mice treated with
15 or 30 mg/kg SB203580, respectively (Figure 6B). This
suggests that prolonged treatment with SB203580 signifi-
cantly reduced tumor burden within the bone. To
determine the effects of p38 MAPK inhibition on 66.1 cell
growth, an in vitro sulforhodamine-B assay was carried
out. On treatment with SB203580 for 2 days at 20 μM
concentration, the number of viable cells was significantly
reduced indicating that p38 MAPK is an important deter-
minant of the growth of 66.1 cells and its blockade results
into decreased cell number (Figure 6C).
Discussion
Our data show that (a) acute and prolonged inhibition of
p38 MAPK blocks non-evoked pain behaviors as mea-
sured by flinching and guarding, but not response thresh-
olds to evoked stimuli; (b) prolonged blockade of p38
MAPK attenuates tumor-induced bone remodeling; and
(c) prolonged blockade of p38 MAPK diminishes tumor
growth within the bone. These data indicate that compo-
nents of cancer-induced bone pain that may reflect
ongoing pain and evoked hypersensitivity are likely dri-
ven by independent mechanisms. These findings suggest
that tumor-induced ongoing pain is dependent on p38
MAPK signaling. However, inhibition of p38 MAPK sig-
naling is insufficient to block hypersensitivity to evoked
stimuli, which may be dependent on establishment of
altered central processing (i.e., central sensitization).
Importantly, we demonstrate that chronic inhibition of
p38 MAPK failed to attenuate tactile hypersensitivity
despite markedly diminished tumor within the bone and
bone remodeling, suggesting potential distinction
between anti-tumor activity and tactile hypersensitivity.
Previous studies in mice have demonstrated increased
phosphorylated p38 MAPK in the DRG and spinal cord
dorsal horn neurons ipsilateral to osteosarcoma treated
femurs [27] and in spinal microglia [28], indicating poten-
tial peripheral and central actions of p38 MAPK in
cancer-induced bone pain. Activation of p38 MAPK has
been implicated in numerous translational and transcrip-
tional responses implicated in peripheral and spinal sensi-
tization initiated by inflammatory and neuropathic injury
[16,17,29-32]. Previous studies have demonstrated that
p38 MAPK mediates increased transcription of nociceptive
peptides, such as SP and CGRP, within the DRG [29,33].
Further, p38 MAPK mediates injury-induced increased
production of TRPV1 and TRPA1 within the DRG [30,34],
and trafficking of the TRPV1 channel to the periphery
[30,35,36]. Notably, p38 MAPK drives post-translational
changes implicated in pain such as phosphorylation of the
TRPV1 channel, resulting in reduced activation threshold
and potentiated capsaicin- or proton-evoked responses
[37]. Phosphorylation of the Nav1.8 channel increases cur-
rent density that can increase neuronal excitability under
pathological conditions [38]. Thus, the effects of acute
administration of SB 203580 may be from inhibition of the
direct activation/phosphorylation of pro-nociceptive chan-
nels. As tumor- and osteoclast- induced acidosis of the
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Page 7 of 15Figure 5 (A) Radiograph images of the injected femur on day 13. Breast cancer-induced bone remodeling is reduced in mice that received
systemic administration of SB203580 (15 and 30 mg/kg, i.p., 2× daily, 7 days). Fractures as indicated by arrows were defined as full-thickness
cortical loss. (B) Bone remodeling ratings of all treatment groups show that the breast cancer-induced bone remodeling is observed 7 days
following the surgery, with no difference between drug- and vehicle-treated mice. Breast cancer-treated mice receiving SB203580 (15 and 30
mg/kg, i.p. 2× daily, 7 days) demonstrated reduced bone destruction on day 13 compared with breast cancer-treated mice that received saline.
(C) Treatment with SB203580 reduced the percentage of mice with breast cancer-induced spontaneous fractures compared to vehicle-treated
animals. n = 6-8.
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Page 8 of 15Figure 6 (A) Representative images of H&E staining showing the effects of chronic p38 MAPK inhibition on cancer treated bones.
Panels a and b demonstrate that breast cancer cells filled the intramedullary space of the femur within 13 days following injection. In addition,
areas of new bone growth were evident within the intramedullary space in the breast cancer-treated mice treated with vehicle. The cortical
bone displayed an uneven look showing tumor invasion into the bone. Panels c - f show that systemic delivery of the p38 MAPK inhibitor (15
and 30 mg/kg, i.p., 2× daily) across 7 days diminished tumor burden, blocked the new bone growth within the intramedullary space and
reduced the invasion of breast cancer cells into the cortical bone. B, cortical bone; M, bone marrow; T, tumor; EP, epiphyseal plate; WB, woven
bone. (B) Quantification of tumor bearing area show two fold reduction in mice treated with 15 mg/kg and five-fold reduction in mice treated
with 30 mg/kg of SB203580 as compared to vehicle treated mice (n = 4-5). Graph shows mean ± SEM. *indicates significant difference from
vehicle-treated bones (p < 0.05) (C) Sulforhodamine B (SRB) assay shows dose dependent reduction in cell viability on treatment of breast cancer
cells with SB203580 for 48 h as compared to the breast cancer cells treated with vehicle alone (n = 3). Graph shows means ± SEM. *Indicates
significant difference from DMSO-treated (control) group (p < 0.05).
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Page 9 of 15tumor microenvironment are implicated in tumor-induced
bone pain [39], increases in acid sensing channels within
the bone, decreased activation thresholds within the
tumor microenvironment, and increased neuronal excit-
ability, likely result in increased activation of sensory fibers
by factors within the tumor microenvironment. Support-
ing this, blockade of the TRPV1 receptor attenuated osteo-
sarcoma-induced flinching and guarding behavior [39-42].
Thus, prolonged administration of the p38 MAPK inhibi-
tor may diminish cancer-induced ongoing pain behaviors
by multiple mechanisms associated with up-regulation and
trafficking of pronociceptive signaling channels (e.g.,
TRPV1) to the periphery.
Within the tumor microenvironment, multiple disease
related factors sensitize and directly drive nociceptive
afferent fibers [3,43]. In addition to tumor and osteoclast
induced acidosis, mechanical factors, such as compression
and damage to sensory fibers innervating the bone by
tumor growth, or mechanical stress from destabilization of
the bone structure due to tumor induced bone remodeling
may drive afferent activity [3,43]. Such signal may be
amplified due to the phosphorylation of sodium channels
[38]. Moreover, pronociceptive inflammatory mediators
including endothelins, ATP, prostaglandins, growth factors
and pronociceptive cytokines are released from the tumor,
tumor-induced bone resorption, and infiltrating immune
cells such as tumor associated macrophages [3,27,44-48].
These factors are implicated in sensitization and direct
activation of sensory fibers [3,27,44]. Moreover, p38MAPK
has been implicated in release of many of these factors
including release of ATP from tumor associated macro-
phages [44] and release of cytokines [22,23,49,50]. More
recently, systemic administration of a selective p38a
MAPK inhibitor has been shown to inhibit lipopolysac-
charide (LPS)-induced elevation of blood levels of tumor
necrosis factor-alpha (TNFa) in humans [51]. Thus, the
blockade of tumor-induced flinching and guarding beha-
viors may be due to diminished release of factors within
the tumor microenvironment that sensitize primary affer-
ent fibers, thereby lowering thresholds for direct activation
by factors within the bone microenvironment (e.g. acid,
ATP), and directly reducing factors (e.g. ATP) that may
directly drive afferent input from the tumor
microenvironment.
In addition to directly inhibiting release of pronocicep-
tive factors from the tumor and associated immune cells,
administration of the p38 MAPK inhibitor across 7 days
also demonstrated disease modifying effects. Painful bone
metastases in humans, such as prostate and breast cancer,
often have osteolytic and osteoblastic lesions [52,53]. Our
model shows tumor-induced osteolytic lesions by day 10
followed by osteoblastic activity. Prolonged SB203580
treatment completely eliminated the abnormal osteoblastic
structures observed in the vehicle-treated bones by day 13
post-tumor implantation. In addition, radiographic ana-
lyses of bones showed reduced incidences of spontaneous
bone fractures in drug treated bones as compared to those
treated with the vehicle. Thus, blockade of tumor-induced
bone remodeling likely contributed to the blockade of
pain behaviors in cancer bearing mice treated with pro-
longed administration of the p38 MAPK inhibitor. In addi-
tion, histology of bones collected at the end our study
show significant tumor reduction with prolonged drug
treatment. Moreover, administration of the p38 MAPK
inhibitor to cultured 66.1 cells diminished viability, indi-
cating a role of p38 MAPK in tumor growth. This is con-
sistent with multiple reports implicating p38 MAPK
in proliferation, invasion and migration of a variety of
malignancies including breast cancer [54-58]. These
tumorigenic effects of p38 MAPK may be mediated by
modulation of transcription factors (e.g. NF-B[ 5 9 , 6 0 ] )
and regulation of anti-apoptotic inflammatory signals (e.g.
interleukin-6 (IL-6) [61]). SB203580 has been demon-
strated to inhibit cyclooxygenase-1 and -2 (COX-1 and 2)
[62]. This is notable as COX-2 inhibitors have been
demonstrated to diminish tumor growth within bone,
bone loss and bone pain in a mouse model of sarcoma-
induced bone pain [63]. We demonstrate that treatment
with 15 mg/kg of SB203580 restricted tumor growth to
the shaft of the bone, with absence of tumor growth into
the epiphyseal plate region.A tah i g h e rd o s e ,3 0m g / k g ,
only small pockets of tumor were seen. We note that this
is in contrast with previous reports that administration of
a p38 MAPK inhibitor across 9-11 days failed to inhibit
growth of osteosarcoma cells within the mouse femur
[27]. These discrepant results may be due to numerous
factors including route of administration (food chow as
opposed to twice daily i.p. injections), and cell lines used
(osteosarcoma vs. murine cell line 66.1 mammary adeno-
carcinoma cells). Our data suggest that diminished tumor
burden and tumor-induced bone remodeling may be key
factors contributing to blockade of tumor-induced flinch-
ing and guarding pain behaviors.
Consistent with previous findings in the osteosarcoma
pain model [27], p38 MAPK inhibition failed to block tac-
tile hypersensitivity. One potential explanation for the
divergent effects of p38 MAPK inhibition on flinching and
guarding as opposed to tactile hypersensitivity is the site
of action. We propose that activation of afferent fibers
innervating the tumor microenvironment drives cancer-
induced ongoing pain whereas central mechanisms med-
iate tactile hypersensitivity. Tactile hypersensitivity is a
measure of referred pain, which likely reflects hypersensi-
tivity to touch stimuli, which is mediated by central sensi-
tization [36]. Previous studies have demonstrated
phosphorylation of p38 MAPK in the spinal cord across
several injury states such as inflammation-induced pain
[17,64] neuropathic pain [16,31,65], spinal injury [66]
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Several studies have demonstrated that spinal administra-
tion of the p38 MAPK inhibitor starting before or at the
time of injury blocks evoked pain (tactile and thermal
hypersensitivity) [18,68-70]. In contrast, others have
demonstrated that spinal administration of p38 MAPK
inhibitors after the pain state is established failed to
reverse thermal or tactile hypersensitivity [68,71,72]. Thus,
although p38 MAPK is implicated in initiation of spinal
sensitization, it does not appear to be a factor in maintain-
ing central sensitization and the associated thermal or tac-
tile hypersensitivity. We propose that growth of the tumor
within the bone and the associated afferent drive may have
established central sensitization required to maintain tac-
tile hypersensitivity prior to drug delivery, as mice demon-
strated flinching, guarding, impaired limb use, and tactile
allodynia within 7 days, prior to drug administration [36].
Therefore, prolonged and acute administration of the p38
MAPK inhibitor blocked apparent spontaneous pain, but
was not sufficient to block the tumor-induced tactile
hypersensitivity. Notably, our findings are consistent with
a recent clinical report in which systemic administration
of a p38 MAPK inhibitor (dilmapimod) to humans with
neuropathic pain diminished pain intensity compared to
placebo, but failed to alter measures of evoked pain,
including tactile allodynia and altered thermal thresholds
[73].
Conclusion
These findings indicate important differences in
mechanisms mediating components of bone cancer
pain. The observation that the p38 MAPK diminished
tumor within the bone indicates that apparent sponta-
neous pain, as measured by flinching and guarding
behaviors, may be dependent on continuing peripheral
drive from the tumor whereas central mechanisms
established prior to diminished tumor burden maintain
evoked pain behaviors. Importantly, this may indicate
different mechanisms might drive ongoing pain as
opposed to evoked pain. A better understanding of how
mechanisms driving multiple components of bone can-
cer pain may lead to a more complete therapeutic treat-
ment strategy.
Methods
Murine cell line: 66.1
Murine cell line 66.1 derived from spontaneously occur-
ring mammary adenocarcinoma was maintained in
advanced Minimum Essesntial Medium, Eagle (aMEM)
(Cellgro Mediatech) containing 10% Fetal bovine serum
(Gemini Bioproducts), 100 units/mL penicillin, and
100 units/mL streptomycin at 37°C and in a 5% CO2
atmosphere. The cells were passaged every 3 days, and
harvested between 12 and 21 passages.
Mouse strain
Female adult Balb/cfC3H mice, weighing 20-25 g (Jackson
Laboratories, Bar Harbor, ME), were chosen for histocom-
patability with the 66.1 cells. All mice were housed maxi-
mum three per cage and used in strict accordance with
the NIH Health Guide for the Care and Use of Laboratory
Animals and the University of Arizona Animal Care
UnitSurgery
Surgery
Baseline radiograph images (Faxitron X-ray Corporation)
of the right femurs were obtained prior to surgery. Ani-
mals were anesthetized with ketamine (80 mg/kg)/xylazine
(12 mg/kg) i.p. and an arthrotomy was performed expos-
ing the condyles of the distal femur as previously described
[74]. A hole was drilled into the femur for injecting the
needle. Needle placement inside the intramedullary space
of the femur was verified using radiograph images and
5 μl of serum-free minimal essential medium (MEM) con-
taining approximately 5 × 10
5 cells was injected into the
intramedullary space of the right femur. For cell-free con-
trols, 5 μl of serum-free MEM alone (no cells) was injected
and sealed into the femur. The injection site was sealed
with dental cement (Simplex).
Drug
SB203580-hydrochloride (Tocris # 1402) (15 mg/kg and
30 mg/kg, i.p.), a selective inhibitor of the activity of p38
MAPK, was dissolved in saline on a heat stir plate at 40°C
in a flask covered with aluminum foil. To determine the
effects of acute administration of SB203580, the drug
was administered 13 days following the injection of 66.1
cells into the femur. To determine the effects of chronic
drug administration, it was administered at two doses
(15 mg/kg and 30 mg/kg, i.p. 2× daily across 7 days start-
ing day 7 post surgery). The animals were divided into
four groups: Cancer-SB203580, Cancer-saline, Control-
SB203580 and control-saline with 10-12 animals in each
group.
Behavioral Analysis
Experimental Design
Each mouse was tested for movement-evoked pain (limb
use), spontaneous pain behaviors (flinching and guarding),
and tactile allodynia prior to surgery (pre-sugery base-
lines). To determine the pain behavior following the injec-
tion of breast cancer cells into the femur, mice were tested
on days 7, 9, 11 and 13 post-surgery. Acute effects of
SB203580 were tested on day 13 post surgery. Pre-drug
analysis of spontaneous pain and tactile allodynia were
obtained for all groups, followed by drug administration.
Behaviors were again assessed at 30, 60, 90, 120 and 180
min following drug administration. All behaviors were
assessed within the same animal. Each animal was first
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dynia. To avoid repeated handling and transferring of ani-
mals from testing chambers to the walking pan at each
time point separated by 30 min for the acute drug studies,
limb use scoring was only carried out for the chronic
administration of SB203580. To study the chronic effects
of SB203580 administration, animals were tested for
movement-evoked pain (limb use), spontaneous pain
behaviors (flinching and guarding), and tactile allodynia
prior to surgery (pre-surgery baselines) following the sur-
gery on days 7 (pre-drug), 9, 11 and 13. The behavioral
tests were carried out at time points later than observed
peak effect of acute administration of the drug. Mice were
first tested for limb use by allowing them to walk in an
empty mouse pan and then placed in testing chambers for
assessment of spontaneous pain and tactile allodynia. All
pain measures were conducted by the experimenter who
was blinded to the treatments.
Spontaneous pain behaviors
All mice were placed in suspended plexiglass chambers
with a wire grid floor and allowed to acclimate to the
chamber for 1 h. Guarding and flinching behaviors were
measured during a 2 min observation period. The num-
ber of flinching episodes and the total time spent guard-
ing the foot of the cancer bearing limb were measured
across 2 minutes for each mouse.
Limb Use
Limb use was assessed as previously described [74]. The
mouse was placed in an empty mouse pan and observed
while walking across the pan in a continuous motion.
Limping and/or guarding behavior of the right (cancer
treated) hind-limb was rated on the following scale: 0 =
complete lack of use, 1 = partial non-use, 2 = limping and
guarding, 3 = limping, 4 = normal walking.
Tactile hypersensitivity
Paw withdrawal thresholds in response to probing with
calibrated von Frey filaments were determined using the
“up-down” method described by Chaplan et al [75].
Mice were kept in suspended cages with wire grid floors
and the von Frey filament applied perpendicularly to the
plantar surface of the ipsilateral paw until it buckled. A
positive response was indicated by a sharp withdrawal of
the paw. An initial probe equivalent to 2 g was applied
and if the response was negative, the stimulus was incre-
mentally increased until a positive response was
obtained, then decreased until a negative result was
obtained. This up-down method was repeated until
three changes in behavior were determined, and the pat-
tern of positive and negative responses was tabulated.
The 50% paw withdrawal threshold was determined as
previously described [76].
Determination of bone destruction and tumor
burden
Radiographical Analysis
To determine the effects of chronic administration of
SB203580, radiographs were taken after behavioral testing
on post-surgery days 7 (pre-drug) and 13 using a Faxitron
machine. Images were captured by a digital camera. Bone
loss was rated by an experimenter blinded to treatment
according to a 5-point scale: 5 = normal bone 4 = epiphy-
seal bone loss, 3 = enhanced bone loss, 2 = osteoblastic
structures 1 = unicortical fractures, 0 = bicortical fractures.
Bone histology
On day 13, following the behavioral testing and radio-
graph imaging, all mice received an overdose of ketamine
(80 mg/kg)/xylazine (12 mg/kg) i.p. and were perfused
transcardially with saline followed by 10% neutral-buf-
f e r e df o r m a l i n( S i g m a ,S t .L o u i s ,M O ,U S A ) .F e m u r s
were collected from the right (cancer-treated) leg and
postfixed overnight in 10% neutral buffered formalin.
Femurs were rinsed in water to remove formalin and
then placed in Decal solution (RDO-Apex, Aurora, IL),
for an hour to achieve decalcification. Samples were
dehydrated in graded ethanol solution before carefully
embedding in paraffin. They were oriented so that the
entire length of the femur could be longitudinally sec-
tioned. Sections 3 μm thick were stained with hematoxy-
lin and eosin to visualize normal marrow elements and
cancer cells under bright field microscopy. The speci-
mens were observed using an Olympus microscope and
images were collected using an Olympus color camera
with proprietary software. For image analysis, bone his-
tology images were analyzed using image J (NIH). Area
occupied by tumor was presented as percent of the total
area of the intramedullary space within the bone, calcu-
lated as: (tumor area/total area)*100.
In vitro analysis of breast cancer cell growth
The 66.1 cells were maintained in MEM media as men-
tioned above. To evaluate the effect of SB203580 on
tumor cell growth, 66.1 cells were treated with 10 or 20
μM of SB203580. Cells treated with 4% DMSO grown at
t h es a m et i m es e r v e da sc o n t r o l s .C e l l sw e r es e e d e da t
15000 cells/well in 6-well plates in complete media for 36
h. When cells reached the confluency of 30-50%, they
were serum starved overnight with serum free optiMEM
media. After 48 h of drug treatment, cell growth was
arrested by slowly adding 50% Tri-chloro acetate (TCA)
and the cells were kept at 4°C for a minimum of 1 h. All
cells were then washed with distilled water 4-5 times and
then treated with 1 ml of sulforhodamine-B (SRB) dye for
10-15 min at room temperature. The cells were again
washed with distilled water 4-5 times. They were then pre-
cipitated in 0.1% acetic acid on a shaker for 10 min. The
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mean OD540 in the SB203580-treated cells is compared to
that of the control done in parallel. Normalized data from
three independent experiments are expressed as means ±
SEM.
Statistical Analysis
Statistical comparisons between treatment groups were
done using one or two way ANOVA. Post-hoc compari-
sons between groups were done using Bonferroni post-
hoc test. To determine the correlation between tumor-
induced bone remodeling and tumor-induced pain beha-
viors, linear regression analysis was carried out. No cor-
relation was found between bone remodeling and pain
behaviors (R < 0.35, p < 0.05). Therefore, data for all ani-
mals were analyzed together. For all analysis, significance
was set at p < 0.05.
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